Products with Anti-diabetic bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN5506 | Asiatic acid |
| Asiatic acid shows antihyperlipidemic, anti-inflammatory, antioxidant, and anti-tumorigenesis effects, it inhibits NLRP3 inflammasome activation, NO and COX-2 signals. Asiatic acid inhibits the expression NDR1/2 kinase and promotes the stability of p21WAF1/CIP1 protein through attenuating NDR1/2 dependent phosphorylation of p21WAF1/CIP1 in HepG2 cells. | |
| BCN5521 | Atraric acid |
| Atraric acid derivatives as a new chemical lead structure for novel therapeutic compounds as AR antagonists, that can be used for prophylaxis or treatment of prostatic diseases. It inhibits PTP1B activity in a dose-dependent manner with IC50 values of 51.5 uM, suggest that atraric acid has potential to treat diabetes. | |
| BCN5534 | Boldine |
| Boldine displays anti-cancer, cytoprotective , anti-oxidant and anti-inflammatory activities. Boldine reduces oxidative stress and improves endothelium-dependent relaxation in aortas of diabetic mice largely through inhibiting ROS overproduction associated with Ang II-mediated BMP4-dependent mechanisms. Boldine may attenuate the catecholamine oxidation-induced brain mitochondrial dysfunction and decrease the dopamine-induced death of PC12 cells through a scavenging action on reactive oxygen species and inhibition of melanin formation and thiol oxidation. | |
| BCN5540 | Bergenin |
| Bergenin is a potent antinarcotic agent, has antiviral ,antifungal, antiarrhythmic, antitumor, antiinflammatory, potent immunomodulatory, antitussive, antiulcerogenic,anti-plasmodial, anti-hepatotoxic and wound healing activities. Bergenin has antidiabetic activity, could be classified as a new group of α-glucosidase inhibitors. Bergenin reduces the expression of NO, TNF-α, IL-1β, and IL-6 proinflammatory cytokines by inhibiting the activation of the NF-κB and MAPKs signaling pathways, and it may represent a novel treatment strategy for mastitis. | |
| BCN5725 | Lupeol |
| 1. Lupeol has a potential to act as an anti-inflammatory, anti-microbial, anti-protozoal, anti-proliferative, anti-invasive, anti-angiogenic, antimalarial and cholesterol lowering agent. 2. Lupeol prevents acetaminophen-induced in vivo hepatotoxicity by altering the Bax/Bcl-2 and oxidative stress-mediated mitochondrial signaling cascade. 3. Lupeol and its ester derivative have beneficial effects on hypercholesterolemia-induced oxidative and inflammatory stresses. 4. Lupeol significantly enhances the radiosensitivity of SMMC-7721 cells in vitro and in vivo. 5. Lupeol shows antidiabetic and antioxidant potential in experimental hyperglycaemia. 6. Lupeol has potential anticancer effect against hepatocellular and pancreatic cancer, by inhibiting cell proliferation, inducing apoptosis and blocking Akt/PI3K and Wnt signaling pathway. 7. Lupeol has antiangiogenic effects, it (at 50 and 30 microg/mL) shows a marked inhibitory activity on human umbilical venous endothelial cells (HUVEC) tube formation while it does not affect the growth of tumor cell lines such as SK-MEL-2, A549, and B16-F10 melanoma. | |
